Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

INMBBullishCorporate Developmentsnews

High materiality8/10

INmune Bio advances UK MHRA pre-MAA for Ebstrocel, targets Feb 2027 MAA

Oct 21, 2026, 7:30 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Regulatory milestones coupled with accelerated manufacturing progress reduce timeline risk and could re-rate the pipeline value; potential UK revenue if approved, though depend on MHRA outcomes and data readouts.

AI summary

What happened, with direct paths to the underlying reporting

INmune Bio said it submitted the final pre-MAA package to the UK MHRA for Ebstrocel (CORDStrom) to treat RDEB. The company expects a full MAA submission in February 2027, with potential UK approval in mid-2027, contingent on MHRA review. If approvals proceed, the therapy could add meaningful pipeline value, though timelines and outcomes remain regulatory-dependent.

INmune Bio submits final pre-MAA to UK MHRA for Ebstrocel RDEB.
Faster manufacturing progress supports full MAA submission in Feb 2027.
Strategy updated: full MAA Feb 2027, UK approval mid-2027, subject to MHRA.
Ebstrocel (CORDStrom) is investigational; regulatory timeline hinges on MHRA.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.